Potentiating activities of chrysin in the therapeutic efficacy of 5‑fluorouracil in gastric cancer cells

Lee,Sunyi; Lee,Suk Kyeong; Jung,Joohee

doi:10.3892/ol.2020.12285

Potentiating activities of chrysin in the therapeutic efficacy of 5‑fluorouracil in gastric cancer cells

Authors:
- Sunyi Lee
- Suk Kyeong Lee
- Joohee Jung
View Affiliations

Affiliations: Duksung Innovative Drug Center, Duksung Women's University, Seoul 01369, Republic of Korea, Department of Medical Life Sciences, Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
Published online on: November 11, 2020 https://doi.org/10.3892/ol.2020.12285
Article Number: 24
Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence and mortality rates of gastric cancer rank among the highest five of all cancer types worldwide. The chemotherapeutic agent 5‑fluorouracil (5‑FU) is the gold standard for treating gastric cancer, but its efficacy is limited due to high rates of resistance. To improve the therapeutic efficacy of 5‑FU and overcome its resistance, the synergistic effect of chrysin with 5‑FU was investigated and its mechanism was elucidated. Chrysin was co‑administered with 5‑FU in AGS cells and 5‑FU‑resistant AGS cells (AGS/FR). Cytotoxicity was investigated using MTT assay, followed by calculating the combination index (CI). Several biomarkers were detected using western blotting analysis. Apoptosis and cell cycle distribution were measured by flow cytometry. The combination of chrysin and 5‑FU significantly increased cytotoxicity more than chrysin or 5‑FU alone. 5‑FU induced apoptosis through p53‑p21 activity, while chrysin arrested the cell cycle in the G2/M phase. The combination of chrysin and 5‑FU showed an anticancer effect via S phase arrest. The results indicated that chrysin and 5‑FU exhibited anticancer properties via different pathways. Furthermore, the present study found that chrysin enhanced the chemotherapeutic effect of 5‑FU in AGS/FR cells. In the resistant cells, the combination of chrysin and 5‑FU improved the anticancer effect via G2/M phase arrest. These findings indicated that chrysin potentiated the chemotherapeutic effect of 5‑FU in gastric cancer AGS and AGS/FR cells via cell cycle arrest. Therefore, chrysin may be used to treat gastric cancers that have become resistant to 5‑FU.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
3	Yu B and Xie J: Identifying therapeutic targets in gastric cancer: The current status and future direction. Acta Biochim Biophys Sin (Shanghai). 48:90–96. 2016.PubMed/NCBI
4	Kimchi-Sarfaty C, Ben-Nun-Shaul O, Rund D, Oppenheim A and Gottesman MM: In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer. Hum Gene Ther. 13:299–310. 2002. View Article : Google Scholar : PubMed/NCBI
5	Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
6	Thomas DM and Zalcberg JR: 5-fluorouracil: A pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol. 25:887–895. 1998. View Article : Google Scholar : PubMed/NCBI
7	Jung J: Emerging utilization of chrysin using nanoscale modification. J Nanometer. 2016:72016.
8	Pal-Bhadra M, Ramaiah MJ, Reddy TL, Krishnan A, Pushpavalli SN, Babu KS, Tiwari AK, Rao JM, Yadav JS and Bhadra U: Plant HDAC inhibitor chrysin arrest cell growth and induce p21WAF1 by altering chromatin of STAT response element in A375 cells. BMC Cancer. 12:1802012. View Article : Google Scholar : PubMed/NCBI
9	Lin YM, Chen CI, Hsiang YP, Hsu YC, Cheng KC, Chien PH, Pan HL, Lu CC and Chen YJ: Chrysin attenuates cell viability of human colorectal cancer cells through autophagy induction unlike 5-fluorouracil/oxaliplatin. Int J Mol Sci. 19:17632018. View Article : Google Scholar
10	Xia Y, Lian S, Khoi PN, Yoon HJ, Joo YE, Chay KO, Kim KK and Do Jung Y: Chrysin inhibits tumor promoter-induced MMP-9 expression by blocking AP-1 via suppression of ERK and JNK pathways in gastric cancer cells. PLoS One. 10:e01240072015. View Article : Google Scholar : PubMed/NCBI
11	Sawicka D, Car H, Borawska MH and Niklinski J: The anticancer activity of propolis. Folia Histochem Cytobiol. 50:25–37. 2012. View Article : Google Scholar : PubMed/NCBI
12	Schumacher M, Hautzinger A, Rossmann A, Holzhauser S, Popovic D, Hertrampf A, Kuntz S, Boll M and Wenzel U: Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters. Biochem Pharmacol. 80:471–479. 2010. View Article : Google Scholar : PubMed/NCBI
13	Gyémánt N, Tanaka M, Antus S, Hohmann J, Csuka O, Mándoky L and Molnár J: In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells. In vivo. 19:367–374. 2005.PubMed/NCBI
14	Hasan MM, Islam MS, Hoque KMF, Haque A and Reza MA: Effect of Citrus macroptera fruit pulp juice on alteration of caspase pathway rendering anti-proliferative activity against Ehrlich's ascites carcinoma in mice. Toxicol Res. 35:271–277. 2019. View Article : Google Scholar : PubMed/NCBI
15	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
16	Ittiudomrak T, Puthong S, Roytrakul S and Chanchao C: α-Mangostin and apigenin induced cell cycle arrest and programmed cell death in SKOV-3 ovarian cancer cells. Toxicol Res. 35:167–179. 2019. View Article : Google Scholar : PubMed/NCBI
17	Jung J, Song DY, Hwang JJ, Park HJ, Lee JS, Song SY, Jeong SY and Choi EK: Induction of p53-mediated senescence is essential for the eventual anticancer therapeutic effect of RH1. Arch Pharm Res. 42:815–823. 2019. View Article : Google Scholar : PubMed/NCBI
18	Lim HK, Kim KM, Jeong SY, Choi EK and Jung J: Chrysin increases the therapeutic efficacy of docetaxel and mitigates docetaxel-induced edema. Integr Cancer Ther. 16:496–504. 2017. View Article : Google Scholar : PubMed/NCBI
19	Li X, Huang JM, Wang JN, Xiong XK, Yang XF and Zou F: Combination of chrysin and cisplatin promotes the apoptosis of Hep G2 cells by up-regulating p53. Chem Biol Interact. 232:12–20. 2015. View Article : Google Scholar : PubMed/NCBI
20	Rasouli S and Zarghami N: Synergistic growth inhibitory effects of chrysin and metformin combination on breast cancer cells through hTERT and cyclin D1 suppression. Asian Pac J Cancer Prev. 19:977–982. 2018.PubMed/NCBI
21	Tao J, Zhi X, Tian Y, Li Z, Zhu Y, Wang W, Xie K, Tang J, Zhang X, Wang L and Xu Z: CEP55 contributes to human gastric carcinoma by regulating cell proliferation. Tumour Biol. 35:4389–4399. 2014. View Article : Google Scholar : PubMed/NCBI
22	Matsuoka T and Yashiro M: The role of PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel). 6:1441–1463. 2014. View Article : Google Scholar : PubMed/NCBI
23	Khoo BY, Chua SL and Balaram P: Apoptotic effects of chrysin in human cancer cell lines. Int J Mol Sci. 11:2188–2199. 2010. View Article : Google Scholar : PubMed/NCBI
24	Agarwal ML, Agarwal A, Taylor WR, Chernova O, Sharma Y and Stark GR: A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc Natl Acad Sci USA. 95:14775–14780. 1998. View Article : Google Scholar : PubMed/NCBI
25	Kim EJ, Kang GJ, Kang JI, Boo HJ, Hyun JW, Koh YS, Chang WY, Kim YR, Kwon JM, Maeng YH, et al: Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells. Oncotarget. 9:19911–19928. 2018. View Article : Google Scholar : PubMed/NCBI